<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04125550</url>
  </required_header>
  <id_info>
    <org_study_id>Cyanotic children</org_study_id>
    <nct_id>NCT04125550</nct_id>
  </id_info>
  <brief_title>Propofol vs Sevoflurane in Cyanotic Congenital Heart Disease</brief_title>
  <acronym>PSI</acronym>
  <official_title>The Anti-inflammatory and Anti-oxidant Effects of Propofol and Sevoflurane in Children With Cyanotic Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cukurova University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cukurova University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The stress response to surgery compromises a series of humoral, metabolic, or cellular&#xD;
      reactions. Cardiac surgery with use of cardiopulmonary bypass (CPB) is a major activator of&#xD;
      the systemic inflammatory response (SIRS). Inflammation, resulting in neutrophil activation,&#xD;
      plays a central role in the production of reactive oxygen species (ROS). Inflammatory and&#xD;
      oxidative reactions may play a role in the more frequent observation of postoperative&#xD;
      ventricular dysfunction in patients with cyanotic congenital heart disease (CHD) undergoing&#xD;
      surgery. The aim of this study is to compare the anti-inflammatory and anti-oxidative effects&#xD;
      of propofol and sevoflurane in children with cyanotic CHD undergoing open heart surgery with&#xD;
      CPB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The stress response to surgery compromises a series of humoral, metabolic, or cellular&#xD;
      reactions. Cardiac surgery with use of cardiopulmonary bypass (CPB) is a major activator of&#xD;
      the systemic inflammatory response (SIRS). Inflammation, resulting in neutrophil activation,&#xD;
      plays a central role in the production of reactive oxygen species (ROS) Despite significant&#xD;
      refinements over the years, oxidative stress and inflammation remain major concerns when&#xD;
      using CPB.&#xD;
&#xD;
      SIRS was more prevalent in patients operated for tetralogy of Fallot and cyanotic syndromes.&#xD;
      It has been shown that pro-inflammatory cytokines are present in the myocardium of patients&#xD;
      with congenital heart disease and concentrations are higher in cyanotic patients than in&#xD;
      acyanotic patients. During CPB, more free oxygen radical production occurs in response to&#xD;
      reoxygenation after chronic cyanosis. Inflammatory and oxidative reactions may play a role in&#xD;
      the more frequent observation of postoperative ventricular dysfunction in patients with&#xD;
      cyanotic congenital heart disease (CHD) undergoing surgery.&#xD;
&#xD;
      Propofol has been suggested as a useful adjunct to CPB because of its potential protective&#xD;
      effect on the heart mediated by a decrease in ischemia-reperfusion injury and inflammation at&#xD;
      clinically relevant concentrations. The anti-inflammatory potential of sevoflurane has been&#xD;
      confirmed in several clinical studies, including patients undergoing cardiac surgery with the&#xD;
      use of CPB.&#xD;
&#xD;
      The goal of anesthetic management of children with CHD is to ensure an ongoing intraoperative&#xD;
      and postoperative cardiovascular stability with attenuation of the stress response and&#xD;
      nociceptive stimulation. Postoperative morbidity and mortality may be reduced by anesthetic&#xD;
      agents which prevent inflammatory and oxidative reactions. The aim of this study is to&#xD;
      compare the anti-inflammatory and anti-oxidative effects of propofol and sevoflurane in&#xD;
      children with cyanotic CHD undergoing open heart surgery with CPB.&#xD;
&#xD;
      Forty patients aged 1-10 years undergoing open heart surgery for cyanotic congenital heart&#xD;
      disease will be included in the study.Patients will be randomly divided into two groups.&#xD;
&#xD;
      In Group S, sevoflurane inhalation (2-8%), 5 microgr/kg intravenous (iv) fentanyl will be&#xD;
      administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle&#xD;
      relaxant. 2% sevoflurane inhalation and 5 µg/kg/h fentanyl infusion will be administered for&#xD;
      the maintenance of anesthesia.&#xD;
&#xD;
      In Group P, 2-3 mg/kg propofol, 5 µg/kg iv fentanyl will be administered for anesthesia&#xD;
      induction and 0.6 mg/kg rocuronium will be used as muscle relaxant. 10 mg/ kg/h propofol&#xD;
      infusion and 5 µg/kg/h fentanyl infusion will be administered for the maintenance of&#xD;
      anesthesia..&#xD;
&#xD;
      Blood samples were collected at four time points: before operation (T0), after release of the&#xD;
      aortic cross-clamp (T1), at the end of the operation (T2), 24 h after the operation (T3). The&#xD;
      blood samples were centrifuged at 1,000xg for 15 min and the serum samples were stored at -80&#xD;
      0C until analysis.&#xD;
&#xD;
      Serum interleukin-6 (IL-6) and tumor necrosis alpha (TNF-alpha) levels and the activities of&#xD;
      total oxidant ve anti-oxidant levels will be measured.&#xD;
&#xD;
      In the postoperative period, age-specific SIRS criteria determined by the International&#xD;
      Pediatric Sepsis Consensus Conference will be used. Patients will be evaluated for SIRS&#xD;
      diagnosis at 6, 12 and 24 hours postoperatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin-6 level at postoperative 24.hours</measure>
    <time_frame>Interleukin-6 level at postoperative 24.hours</time_frame>
    <description>Serum interleukin-6 (IL-6) level will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor alpha (TNF-alpha) level</measure>
    <time_frame>Serum TNF-alpha level at postoperative 24.hours</time_frame>
    <description>Serum TNF-alpha level will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total oxidant and anti-oxidant levels</measure>
    <time_frame>Serum total oxidant and anti-oxidant levels at postoperative 24.hours</time_frame>
    <description>Serum total oxidant and anti-oxidant levels will be measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cyanotic Congenital Heart Disease</condition>
  <condition>Pediatric HD</condition>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Group P, 2-3 mg/kg propofol, 5 µg/kg iv fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 10 mg/kg/h propofol infusion and 5 µg/kg/h fentanyl infusion will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group S</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Group S, sevoflurane inhalation (2-8%), 5 microgr/kg intravenous (iv) fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 2% sevoflurane inhalation and 5 µg/kg/h fentanyl infusion will be administered for the maintenance of anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>2-3 mg/kg propofol will be administered for anesthesia induction. 10 mg/ kg/h propofol infusion will be administered for the maintenance of anesthesia.</description>
    <arm_group_label>Group P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>sevoflurane inhalation (2-8%) will be administered for anesthesia induction. 2% sevoflurane inhalation will be administered for the maintenance of anesthesia.</description>
    <arm_group_label>Group S</arm_group_label>
    <other_name>Sevorane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1-10 years old&#xD;
&#xD;
          -  Patients with cyanotic congenital heart disease undergoing open heart surgery with CPB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with liver or renal dysfunction&#xD;
&#xD;
          -  Patients with inflammatory disease&#xD;
&#xD;
          -  Patients with hemostatic disorders&#xD;
&#xD;
          -  Preoperative use of anti-inflammatory and/or antioxidant drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feri̇de Karacaer</last_name>
    <role>Study Director</role>
    <affiliation>Çukurova Üniversitesi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feri̇de Karacaer</last_name>
    <phone>+905062628416</phone>
    <email>feridekaracaer@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cukurova University</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feride Karacaer, Specialist</last_name>
      <phone>+90322 3386060</phone>
      <phone_ext>3264</phone_ext>
      <email>feridekaracaer@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cukurova University</investigator_affiliation>
    <investigator_full_name>Feride Karacaer</investigator_full_name>
    <investigator_title>Asisstant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

